RECOVERY FORCE, LLC — Department of Health and Human Services SBIR Phase I: NHLBI
RECOVERY FORCE, LLC — SBIR Phase I award from Department of Health and Human Services.
- Amount
- $244,167
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase I
- Topic
- NHLBI
- Solicitation
- PA15-269
- NAICS
- —
- Place of performance
- IN
- Period
- 2017-02-01 → 2018-07-31
Description
Project Abstract Deep Vein Thrombosis DVT is a condition wherein a blood clot forms in a vein of the deep system These clots can break loose travel through the blood stream and into the lungs causing pulmonary embolism PE This is life threatening and requires immediate medical care Each year in the United States between and people get a blood clot in the legs or in the lungs with associated costs $ B annually DVT and pulmonary embolism PE effect per people and in those in Estimates suggest Americans die of DVT PE annually will die within one month of diagnosis and sudden death is the first symptom in of people with PE Of those with DVT will have long term complications will have a recurrence within years The current standard of care for DVT PE are blood thinners clot busters given through an IV filters inserted into the vena cava long term use of compression stockings for prevention and DVT cuffs which are polypropylene air bladder wraps attached to hoses and a pump then placed around the lower extremities The current standards of care are reactive to the diagnosis invasive and expensive Further they are uncomfortable and cumbersome which significantly reduces patient compliance rates In this SBIR Recovery Force an Indiana based small business will use phase change memory technology integrated logic and a rechargeable power source to create a new DVT cuff design The comfortable wearable technology will proactively address the risk of DVT PE with increased patient compliance for people at risk of DVT PE including individuals with diabetes the elderly pregnant women and cancer as well as post operative patients Recovery Force will achieve the following Phase I Aims Aim Conduct Comparative Engineering Testing Determine that desired benchmark is consistent with available DVT cuffs in clinical use with an air bladder pressures cycle time contact area and temperature All design and testing requirements will be performed under the Recoveryandapos s Forceandapos s quality system ISO in preparation for a FDA k Class II medical device submission Aim Conduct a preliminary clinical usability study to assess comfort acceptance ease of use and design The primary hypothesis is following optimizing the prototype participants will be strongly statisfied with design comfort and wearability of the product It is also predicted that their acceptance to wearing the device will be high The PI will work with subawardee Dr Armstrong UofAz to conduct a preliminary usability study At the conclusion of Phase I the Recovery Force will have demonstrated the feasibility of a new DVT focused compression product that will allow the user to be mobile be made out of comfortable material achieve similar or better results than existing solutions and offer increased patient compliance Phase II will focus on a larger scale multi site trial for use in the healthcare market with testing in recovery rooms and long term care facilities Project Relevance Each year as many as Americans are affected by deep vein thrombosis DVT and pulmonary embolisms PE resulting in $ billion in health care costs annually Individuals at risk of developing DVT or PE are often given a cuff s that delivers gentle compressions created by a pump and delivered through a series of tubes leading to an air bladder This solution requires the patient to be bedridden is made of polypropylene and has limited compliance outside the hospital setting In this SBIR Recovery Force will develop a redesigned DVT cuff that will allow patients to be ambulatory during use that can be worn with normal clothing and eliminate the need for tubes and a pump This will increase patient compliance and reduce the morbidity and mortality rates of those Americans suffering from risk factors associated with DVT and PE